Pub Date : 2024-09-18DOI: 10.1186/s12645-024-00286-y
Kaumudi Pande, B. K. Bettadaiah, Anbarasu Kannan
Major therapeutic developments have been made in the prevention of head and neck cancer (HNC), and crucial measures have been implemented for the survival of patients. The advent of cancer nano-theranostic as an effective approach targets cancer by allowing drug aggregation at the tumour site, its proper bioaccessibility, and tumour cell death. Curd exosomes are the cellular interactive nanovesicles, considered a convenient conveyance medium for cargoes still unexplored. Curcumin analogue alanine is primarily recognised for its superior radical scavenging activity and anti-mutagen properties compared with curcumin. The current study focussed on the isolation and characterisation of curd exosomes, followed by their interaction with cancer cells to deliver their content conveniently. Herein, we developed a nanoformulation of curd exosomes loaded with curcumin alanine to determine its bioaccessibility and anti-proliferative effect compared with curcumin alanine free drug. In addition, the influence of curcumin alanine and its nanoformulation on cell morphology, nucleus structures, colony formation potential, and tumour cell death was observed. The expression of EphA2 and its associated molecules was determined using western blot and PCR to explore the mechanism at the cellular level. The recent investigation revealed the encapsulation of curcumin analogue alanine in curd exosomes enhanced the bioaccessibility in contrast with curcumin alanine. Then, we focussed on the curcumin alanine effect on HNC cells to monitor morphological alterations, a reduction in cell multiplication, and triggering apoptosis. Particularly, we found considerable suppression of EphA2 influencing mitochondrial dynamics with the strengthening of mitochondrial fusion MFN1 and MFN2, whereas fission-associated protein DRP1 was down-regulated by the treatment of curcumin alanine nanoformulation. Furthermore, curcumin alanine nanoformulation activates the apoptotic marker caspase-7 and suppresses the anti-apoptotic marker Bcl-xL. Hence, these findings have drawn attention to curd exosomes loaded curcumin alanine nanoformulation impairing cell multiplication and mitochondrial fission, leading to apoptotic cell death, as one of the effective approaches for the treatment of HNC.
{"title":"A biocompatible nanoformulation of curcumin analogue and curd exosomes targeting EphA2 signalling cascade in head and neck cancer","authors":"Kaumudi Pande, B. K. Bettadaiah, Anbarasu Kannan","doi":"10.1186/s12645-024-00286-y","DOIUrl":"https://doi.org/10.1186/s12645-024-00286-y","url":null,"abstract":"Major therapeutic developments have been made in the prevention of head and neck cancer (HNC), and crucial measures have been implemented for the survival of patients. The advent of cancer nano-theranostic as an effective approach targets cancer by allowing drug aggregation at the tumour site, its proper bioaccessibility, and tumour cell death. Curd exosomes are the cellular interactive nanovesicles, considered a convenient conveyance medium for cargoes still unexplored. Curcumin analogue alanine is primarily recognised for its superior radical scavenging activity and anti-mutagen properties compared with curcumin. The current study focussed on the isolation and characterisation of curd exosomes, followed by their interaction with cancer cells to deliver their content conveniently. Herein, we developed a nanoformulation of curd exosomes loaded with curcumin alanine to determine its bioaccessibility and anti-proliferative effect compared with curcumin alanine free drug. In addition, the influence of curcumin alanine and its nanoformulation on cell morphology, nucleus structures, colony formation potential, and tumour cell death was observed. The expression of EphA2 and its associated molecules was determined using western blot and PCR to explore the mechanism at the cellular level. The recent investigation revealed the encapsulation of curcumin analogue alanine in curd exosomes enhanced the bioaccessibility in contrast with curcumin alanine. Then, we focussed on the curcumin alanine effect on HNC cells to monitor morphological alterations, a reduction in cell multiplication, and triggering apoptosis. Particularly, we found considerable suppression of EphA2 influencing mitochondrial dynamics with the strengthening of mitochondrial fusion MFN1 and MFN2, whereas fission-associated protein DRP1 was down-regulated by the treatment of curcumin alanine nanoformulation. Furthermore, curcumin alanine nanoformulation activates the apoptotic marker caspase-7 and suppresses the anti-apoptotic marker Bcl-xL. Hence, these findings have drawn attention to curd exosomes loaded curcumin alanine nanoformulation impairing cell multiplication and mitochondrial fission, leading to apoptotic cell death, as one of the effective approaches for the treatment of HNC. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"75 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142255891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-06DOI: 10.1186/s12645-024-00289-9
Atiyeh Ale-Ahmad, Sohrab Kazemi, Abdolreza Daraei, Mahdi Sepidarkish, Ali Akbar Moghadamnia, Hadi Parsian
Developing a drug delivery system that can transport a higher concentration to the target cells can improve therapeutic efficacy. This study aimed to develop a novel delivery system for acetyl-11-keto-beta-boswellic Acid (AKBA) using chitosan-sodium alginate–calcium chloride (CS-SA-CaCl2) nanoparticles. The objectives were to evaluate the antiproliferative activity of these nanoparticles against colorectal cancer (CRC) cells and to improve the bioavailability and therapeutic efficacy of AKBA. With an extraction efficiency of 12.64%, AKBA was successfully extracted from the gum resin of B. serrata. The nanoparticle delivery system exhibited superior cytotoxicity against HT29 cells compared to free AKBA, AKBA extract (BA-Ex), and 5-FU. Furthermore, the nanoformulation (nano-BA-Ex) induced apoptosis in HT29 cells more effectively than the other treatments. In vivo results showed that nanoformulation inhibited chemically induced colon tumorigenesis in mice and significantly reduced the number of aberrant crypt foci (ACFs). The developed CS-SA-CaCl2 nanoparticles loaded with AKBA extract exhibit potential as a potent drug delivery mechanism for the colorectal cancer model. Nano-BA-Ex is a promising strategy for enhancing the solubility, bioavailability, and therapeutic efficacy of BA derivatives. With its multiple effects on cancer cells and controlled drug release through nanocapsules, nano-BA-Ex stands out as a compelling candidate for further preclinical and clinical evaluation in CRC therapy.
{"title":"pH-sensitive nanoformulation of acetyl-11-keto-beta-boswellic acid (AKBA) as a potential antiproliferative agent in colon adenocarcinoma (in vitro and in vivo)","authors":"Atiyeh Ale-Ahmad, Sohrab Kazemi, Abdolreza Daraei, Mahdi Sepidarkish, Ali Akbar Moghadamnia, Hadi Parsian","doi":"10.1186/s12645-024-00289-9","DOIUrl":"https://doi.org/10.1186/s12645-024-00289-9","url":null,"abstract":"Developing a drug delivery system that can transport a higher concentration to the target cells can improve therapeutic efficacy. This study aimed to develop a novel delivery system for acetyl-11-keto-beta-boswellic Acid (AKBA) using chitosan-sodium alginate–calcium chloride (CS-SA-CaCl2) nanoparticles. The objectives were to evaluate the antiproliferative activity of these nanoparticles against colorectal cancer (CRC) cells and to improve the bioavailability and therapeutic efficacy of AKBA. With an extraction efficiency of 12.64%, AKBA was successfully extracted from the gum resin of B. serrata. The nanoparticle delivery system exhibited superior cytotoxicity against HT29 cells compared to free AKBA, AKBA extract (BA-Ex), and 5-FU. Furthermore, the nanoformulation (nano-BA-Ex) induced apoptosis in HT29 cells more effectively than the other treatments. In vivo results showed that nanoformulation inhibited chemically induced colon tumorigenesis in mice and significantly reduced the number of aberrant crypt foci (ACFs). The developed CS-SA-CaCl2 nanoparticles loaded with AKBA extract exhibit potential as a potent drug delivery mechanism for the colorectal cancer model. Nano-BA-Ex is a promising strategy for enhancing the solubility, bioavailability, and therapeutic efficacy of BA derivatives. With its multiple effects on cancer cells and controlled drug release through nanocapsules, nano-BA-Ex stands out as a compelling candidate for further preclinical and clinical evaluation in CRC therapy.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"75 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28DOI: 10.1186/s12645-024-00287-x
Xiuyun Lin, Jie Liu, Guangfeng Wu, Xiu Yang, Wenqiang Yan, Nanfeng Fan, Hui Li
Cancer cells can resist chemotherapy through various mechanisms, diminishing treatment outcomes. Research had indicated that combining miR-122 with doxorubicin (DOX) can improve hepatocellular carcinoma (HCC) therapy. To explore this, we created a one-pot co-delivery system, Fe-miR-122/DOX, by coordinating miR-122, DOX, and FeII ions into nanoparticles. These nanoparticles display uniform particle sizes, well-defined morphology, and exceptional colloidal stability in 10% FBS and 20% FBS solution over 24 h. When the ratio of DOX to miR-122 was set at 20:1, the loading efficiency of both drugs reached 54.7% and 55.5%, respectively. Cell experiments confirmed that Fe-miR-122/DOX efficiently delivers both miR-122 and DOX, enabling cytoplasmic delivery through lysosomal escape, facilitated by the positive charge of the nanoparticles. Functionally, miR-122 increases intracellular accumulation of DOX by downregulating P-glycoprotein (P-gp) expression, and it promotes apoptosis by downregulating B-cell lymphoma 2 (Bcl-2), which leads to the upregulation of Caspase-3. Additionally, Fe-miR-122/DOX disrupts cIAPs-mediated anti-apoptotic signals, downregulates PARP-1 expression, hinders DNA repair, promotes DNA fragmentation, enhances caspase-3 expression, and triggers programmed cell death, synergistically enhancing its antitumor efficacy. This synergistic mechanism disrupts DNA repair, amplifying DNA damage and apoptosis. Our cytotoxicity and apoptosis assays (with a HepG2 cell apoptosis rate of 85.98%) demonstrated the potent antitumor capability of Fe-miR-122/DOX. This innovative system has demonstrated good biocompatibility and has the potential to transform HCC therapy. Future research could focus on optimizing the co-delivery system and assessing its efficacy in clinical trials.
癌细胞会通过各种机制抵抗化疗，从而降低治疗效果。研究表明，将 miR-122 与多柔比星（DOX）结合使用可改善肝细胞癌（HCC）的治疗。为了探索这一点，我们将 miR-122、DOX 和 FeII 离子配伍到纳米颗粒中，创建了一种一锅共给药系统--Fe-miR-122/DOX。当 DOX 与 miR-122 的比例设定为 20:1 时，两种药物的负载效率分别达到 54.7% 和 55.5%。细胞实验证实，Fe-miR-122/DOX 能有效地递送 miR-122 和 DOX，通过溶酶体逸出实现胞质递送，而纳米颗粒的正电荷则有助于溶酶体逸出。在功能上，miR-122 通过下调 P-糖蛋白（P-gp）的表达来增加 DOX 的细胞内蓄积，并通过下调 B 细胞淋巴瘤 2（Bcl-2）来促进细胞凋亡，从而导致 Caspase-3 的上调。此外，Fe-miR-122/DOX 还能破坏 cIAPs 介导的抗凋亡信号，下调 PARP-1 的表达，阻碍 DNA 修复，促进 DNA 断裂，增强 Caspase-3 的表达，引发细胞程序性死亡，从而协同增强其抗肿瘤疗效。这种协同机制破坏了 DNA 修复，扩大了 DNA 损伤和细胞凋亡。我们的细胞毒性和细胞凋亡试验（HepG2 细胞凋亡率为 85.98%）表明，Fe-miR-122/DOX 具有强大的抗肿瘤能力。这一创新系统具有良好的生物相容性，有望改变 HCC 治疗方法。未来的研究重点是优化联合给药系统，并在临床试验中评估其疗效。
{"title":"Enhanced chemotherapy response in hepatocellular carcinoma: synergistic effects of miR-122 and doxorubicin co-delivery system inducing apoptosis and DNA damage","authors":"Xiuyun Lin, Jie Liu, Guangfeng Wu, Xiu Yang, Wenqiang Yan, Nanfeng Fan, Hui Li","doi":"10.1186/s12645-024-00287-x","DOIUrl":"https://doi.org/10.1186/s12645-024-00287-x","url":null,"abstract":"Cancer cells can resist chemotherapy through various mechanisms, diminishing treatment outcomes. Research had indicated that combining miR-122 with doxorubicin (DOX) can improve hepatocellular carcinoma (HCC) therapy. To explore this, we created a one-pot co-delivery system, Fe-miR-122/DOX, by coordinating miR-122, DOX, and FeII ions into nanoparticles. These nanoparticles display uniform particle sizes, well-defined morphology, and exceptional colloidal stability in 10% FBS and 20% FBS solution over 24 h. When the ratio of DOX to miR-122 was set at 20:1, the loading efficiency of both drugs reached 54.7% and 55.5%, respectively. Cell experiments confirmed that Fe-miR-122/DOX efficiently delivers both miR-122 and DOX, enabling cytoplasmic delivery through lysosomal escape, facilitated by the positive charge of the nanoparticles. Functionally, miR-122 increases intracellular accumulation of DOX by downregulating P-glycoprotein (P-gp) expression, and it promotes apoptosis by downregulating B-cell lymphoma 2 (Bcl-2), which leads to the upregulation of Caspase-3. Additionally, Fe-miR-122/DOX disrupts cIAPs-mediated anti-apoptotic signals, downregulates PARP-1 expression, hinders DNA repair, promotes DNA fragmentation, enhances caspase-3 expression, and triggers programmed cell death, synergistically enhancing its antitumor efficacy. This synergistic mechanism disrupts DNA repair, amplifying DNA damage and apoptosis. Our cytotoxicity and apoptosis assays (with a HepG2 cell apoptosis rate of 85.98%) demonstrated the potent antitumor capability of Fe-miR-122/DOX. This innovative system has demonstrated good biocompatibility and has the potential to transform HCC therapy. Future research could focus on optimizing the co-delivery system and assessing its efficacy in clinical trials.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"36 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-21DOI: 10.1186/s12645-024-00285-z
Soheila Montazersaheb, Aziz Eftekhari, Amir Shafaroodi, Soodeh Tavakoli, Sara Jafari, Ayşe Baran, Mehmet Fırat Baran, Sevda Jafari, Elham Ahmadian
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Radiation therapy (RT) is a modality for TNBC management. Radiosensitizers can mitigate the adverse effects of RT. Applying green-synthesized silver nanoparticles (Ag-NPs) from biological sources such as plants is a potential strategy to sensitize cancer cells to radiotherapy due to the low toxicity. Therefore, identifying novel natural sources for synthesizing stable and broadly applicable green-Ag-NPs has gained more attention in cancer therapy. In the present study, we synthesized green- Ag-NPs from pumpkin peel extract and elucidated the impact of green-synthesized Ag-NPs as a radiosensitizer in MDA-MB 231 cells (a model of TNBC). The prepared Ag-NPs had a spherical shape with an average size of 81 nm and a zeta potential of − 9.96 mV. Combination of green-synthesized Ag-NPs with RT exhibited synergistic anticancer effects with an optimum combination index (CI) of 0.49 in MDA-MB-231 cells. Green-synthesized Ag-NPs synergistically potentiated RT-induced apoptosis in MDA-MB-231 cells compared to the corresponding monotherapies. Morphological features of apoptosis were further confirmed by the DAPI–TUNEL staining assay. HIF-1α expression was decreased in cells subjected to combination therapy. Bax and p53 expression increased, whereas Bcl-2 genes decreased. Combination therapy significantly increased the protein level of PERK and CHOP while decreasing cyclin D1 and p-ERK/total ERK levels compared to monotherapies. These findings indicate the potential effect of green-synthesized Ag-NPs as a radiosensitizer for TNBC treatment.
{"title":"Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC)","authors":"Soheila Montazersaheb, Aziz Eftekhari, Amir Shafaroodi, Soodeh Tavakoli, Sara Jafari, Ayşe Baran, Mehmet Fırat Baran, Sevda Jafari, Elham Ahmadian","doi":"10.1186/s12645-024-00285-z","DOIUrl":"https://doi.org/10.1186/s12645-024-00285-z","url":null,"abstract":"Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Radiation therapy (RT) is a modality for TNBC management. Radiosensitizers can mitigate the adverse effects of RT. Applying green-synthesized silver nanoparticles (Ag-NPs) from biological sources such as plants is a potential strategy to sensitize cancer cells to radiotherapy due to the low toxicity. Therefore, identifying novel natural sources for synthesizing stable and broadly applicable green-Ag-NPs has gained more attention in cancer therapy. In the present study, we synthesized green- Ag-NPs from pumpkin peel extract and elucidated the impact of green-synthesized Ag-NPs as a radiosensitizer in MDA-MB 231 cells (a model of TNBC). The prepared Ag-NPs had a spherical shape with an average size of 81 nm and a zeta potential of − 9.96 mV. Combination of green-synthesized Ag-NPs with RT exhibited synergistic anticancer effects with an optimum combination index (CI) of 0.49 in MDA-MB-231 cells. Green-synthesized Ag-NPs synergistically potentiated RT-induced apoptosis in MDA-MB-231 cells compared to the corresponding monotherapies. Morphological features of apoptosis were further confirmed by the DAPI–TUNEL staining assay. HIF-1α expression was decreased in cells subjected to combination therapy. Bax and p53 expression increased, whereas Bcl-2 genes decreased. Combination therapy significantly increased the protein level of PERK and CHOP while decreasing cyclin D1 and p-ERK/total ERK levels compared to monotherapies. These findings indicate the potential effect of green-synthesized Ag-NPs as a radiosensitizer for TNBC treatment. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"150 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-17DOI: 10.1186/s12645-024-00282-2
Samir Ali Abd El-Kaream, Doha Farhat Mohamed Zedan, Hagar Mohamed Mohamed, Amal Saleh Mohamed Soliman, Sohier Mahmoud El-Kholey, Mohammed Kamal El-Dein Nasra
Sono-photodynamic therapy (SPDT), which combines photodynamic (PDT) and sonodynamic (SDT) therapies with sensitizers, offers new avenues for cancer treatment. Even though new sensitizers for SPDT have been synthesized with great success, few of them are effectively used. The limited tumor-targeting specificity, inability to transport the sensitizers deeply intratumorally, and the deteriorating tumor microenvironment limit their anti-tumor effectiveness. The current study was carried out aiming at high-frequency ultrasound-assisted drug delivery of chia, cress and flax conjugated hematite iron oxide nanoparticles (CCF–HIONP) for photothermal–photodynamic lung cancer (LCA) treatment in vitro and in vivo as activated cancer treatment up-to-date modality. The study was conducted in vitro on human LCA cells (A-549) and the study protocol application groups in vivo on Swiss albino mice treated with benzo[a]pyrene only and were not received any treatment for inducing LCA, and only after LCA induction the study treatment protocol began, treatment was daily with CCF–HIONP as HIFU–SPDT sensitizer with or without exposure to laser (IRL) or high-frequency ultrasound (HIFU–US) or a combination of laser and/or high-frequency ultrasound for 3 min for 2 weeks. Revealed that HIONP can be employed as effective CCF delivery system that directly targets LCA cells. In addition, CCF–HIONP is a promising HIFU–SPS for HIFU–SPDT and when combined with HIFU–SPDT can be very effective in treatment of LCA–A549 in vitro (cell viability decreased in a dose-dependent basis, the cell cycle progression in G0/G1 was slowed down, and cell death was induced as evidenced by an increase in the population of Pre-G cells, an increase in early and late apoptosis and necrosis, and an increase in autophagic cell death) and benzo[a]pyrene LCA-induce mice in vivo (decreased oxidative stress (MDA), and ameliorated enzymatic and non-enzymatic antioxidants (SOD, GR, GPx, GST, CAT, GSH, and TAC) as well as renal (urea, creatinine) and hepatic (ALT, AST) functions, induced antiproliferative genes (caspase 3,9, p53, Bax, TNFalpha), suppressed antiapoptotic and antiangiogenic genes (Bcl2,VEGF respectively) and effectively reducing the growth of tumors and even leading to cancer cell death. This process could be attributed to photochemical and/or high-frequency sono-chemical activation mechanism HIFU–SPDT. The results indicate that CCF–HIONP has great promise as an innovative, effective delivery system for selective localized treatment of lung cancer that is activated by HIFU–SPDT.
{"title":"High-frequency ultrasound-assisted drug delivery of chia, cress, and flax conjugated hematite iron oxide nanoparticle for sono-photodynamic lung cancer treatment in vitro and in vivo","authors":"Samir Ali Abd El-Kaream, Doha Farhat Mohamed Zedan, Hagar Mohamed Mohamed, Amal Saleh Mohamed Soliman, Sohier Mahmoud El-Kholey, Mohammed Kamal El-Dein Nasra","doi":"10.1186/s12645-024-00282-2","DOIUrl":"https://doi.org/10.1186/s12645-024-00282-2","url":null,"abstract":"Sono-photodynamic therapy (SPDT), which combines photodynamic (PDT) and sonodynamic (SDT) therapies with sensitizers, offers new avenues for cancer treatment. Even though new sensitizers for SPDT have been synthesized with great success, few of them are effectively used. The limited tumor-targeting specificity, inability to transport the sensitizers deeply intratumorally, and the deteriorating tumor microenvironment limit their anti-tumor effectiveness. The current study was carried out aiming at high-frequency ultrasound-assisted drug delivery of chia, cress and flax conjugated hematite iron oxide nanoparticles (CCF–HIONP) for photothermal–photodynamic lung cancer (LCA) treatment in vitro and in vivo as activated cancer treatment up-to-date modality. The study was conducted in vitro on human LCA cells (A-549) and the study protocol application groups in vivo on Swiss albino mice treated with benzo[a]pyrene only and were not received any treatment for inducing LCA, and only after LCA induction the study treatment protocol began, treatment was daily with CCF–HIONP as HIFU–SPDT sensitizer with or without exposure to laser (IRL) or high-frequency ultrasound (HIFU–US) or a combination of laser and/or high-frequency ultrasound for 3 min for 2 weeks. Revealed that HIONP can be employed as effective CCF delivery system that directly targets LCA cells. In addition, CCF–HIONP is a promising HIFU–SPS for HIFU–SPDT and when combined with HIFU–SPDT can be very effective in treatment of LCA–A549 in vitro (cell viability decreased in a dose-dependent basis, the cell cycle progression in G0/G1 was slowed down, and cell death was induced as evidenced by an increase in the population of Pre-G cells, an increase in early and late apoptosis and necrosis, and an increase in autophagic cell death) and benzo[a]pyrene LCA-induce mice in vivo (decreased oxidative stress (MDA), and ameliorated enzymatic and non-enzymatic antioxidants (SOD, GR, GPx, GST, CAT, GSH, and TAC) as well as renal (urea, creatinine) and hepatic (ALT, AST) functions, induced antiproliferative genes (caspase 3,9, p53, Bax, TNFalpha), suppressed antiapoptotic and antiangiogenic genes (Bcl2,VEGF respectively) and effectively reducing the growth of tumors and even leading to cancer cell death. This process could be attributed to photochemical and/or high-frequency sono-chemical activation mechanism HIFU–SPDT. The results indicate that CCF–HIONP has great promise as an innovative, effective delivery system for selective localized treatment of lung cancer that is activated by HIFU–SPDT.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"86 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To investigate the ability of extracellular vesicles (EVs) to deliver oxaliplatin to epidermal growth factor receptor (EGFR+) colorectal cancer cells and increase oxaliplatin’s cytotoxicity. Oxaliplatin was passively loaded into a stable cell line expressing cetuximab in membranes. EVs were collected and characterized for size, and their ability to target EGFR+ cells was tested. Cytotoxicity experiments were performed, and a xenograft cancer animal model was used to confirm the specific accumulation of oxaliplatin-loaded EVs with cetuximab-expressing membranes in EGFR+ cells. EVs with cetuximab-expressing membranes were successfully produced and used to encapsulate oxaliplatin, resulting in consistently sized oxaliplatin-loaded EVs with cetuximab-expressing membranes. The oxaliplatin-loaded EVs with cetuximab-expressing membranes were specifically accumulated by EGFR+ cells, leading to significant cytotoxic effects on these cells. In the animal model, the oxaliplatin-loaded EVs with cetuximab-expressing membranes accumulated specifically in EGFR+ cells and significantly enhanced oxaliplatin’s therapeutic efficacy against EGFR+ cancer cells. EVs with membrane-expressed bioactive molecules are a promising strategy for delivering therapeutic agents to EGFR+ colorectal cancer cells.
{"title":"Maximizing oxaliplatin's impact on EGFR + colorectal cancer through targeted extracellular vesicles","authors":"Shang-Tao Chien, Yi-Jung Huang, Ming-Yii Huang, Yi-Ping Fang, Shi-Wei Chao, Chia-Tse Li, Wun-Ya Jhang, Yun-Han Hsu, Shuo-Hung Wang, Chih-Hung Chuang","doi":"10.1186/s12645-024-00284-0","DOIUrl":"https://doi.org/10.1186/s12645-024-00284-0","url":null,"abstract":"To investigate the ability of extracellular vesicles (EVs) to deliver oxaliplatin to epidermal growth factor receptor (EGFR+) colorectal cancer cells and increase oxaliplatin’s cytotoxicity. Oxaliplatin was passively loaded into a stable cell line expressing cetuximab in membranes. EVs were collected and characterized for size, and their ability to target EGFR+ cells was tested. Cytotoxicity experiments were performed, and a xenograft cancer animal model was used to confirm the specific accumulation of oxaliplatin-loaded EVs with cetuximab-expressing membranes in EGFR+ cells. EVs with cetuximab-expressing membranes were successfully produced and used to encapsulate oxaliplatin, resulting in consistently sized oxaliplatin-loaded EVs with cetuximab-expressing membranes. The oxaliplatin-loaded EVs with cetuximab-expressing membranes were specifically accumulated by EGFR+ cells, leading to significant cytotoxic effects on these cells. In the animal model, the oxaliplatin-loaded EVs with cetuximab-expressing membranes accumulated specifically in EGFR+ cells and significantly enhanced oxaliplatin’s therapeutic efficacy against EGFR+ cancer cells. EVs with membrane-expressed bioactive molecules are a promising strategy for delivering therapeutic agents to EGFR+ colorectal cancer cells. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"5 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><b>Correction: Cancer Nanotechnology (2023) 14:78 </b><b>https://doi.org/10.1186/s12645-023-00230-6</b></p><p>In this article, the author name Tung-Ho Wu was incorrectly written as Dung-Ho Wu. The affiliation of the author is given in this correction.</p><p>The original article has been corrected.</p><h3>Authors and Affiliations</h3><ol><li><p>Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung, 80708, Taiwan</p><p>Huei-Jen Chen, Yi-An Cheng, Bo-Cheng Huang & Tian-Lu Cheng</p></li><li><p>Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Huei-Jen Chen, Yu-Tung Chen, Chia-Ching Li, Shih-Ting Hong & Steve R. Rofer</p></li><li><p>Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Bo-Cheng Huang, I.-Ju Chen, Kai-Wen Ho, Chiao-Yun Chen, Jaw-Yuan Wang & Tian-Lu Cheng</p></li><li><p>Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan</p><p>Tian-Lu Cheng</p></li><li><p>Department of Medical Imaging, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan</p><p>Chiao-Yun Chen</p></li><li><p>School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Chiao-Yun Chen</p></li><li><p>Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan</p><p>Fang-Ming Chen</p></li><li><p>Department of Surgery, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan</p><p>Fang-Ming Chen</p></li><li><p>Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Fang-Ming Chen</p></li><li><p>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan</p><p>Steve R. Rofer</p></li><li><p>Department of Cardiovascular Surgeon, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan</p><p>Tung-Ho Wu</p></li><li><p>School of Medicine, I-Shou University, Kaohsiung, Taiwan</p><p>I.-Ju Chen</p></li></ol><span>Authors</span><ol><li><span>Huei-Jen Chen</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Yi-An Cheng</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Yu-Tung Chen</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Chia-Ching Li</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Bo-Cheng Huang</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Shih-Ting Hong</span>View author publications<p>You can also search for this author in <span>P
复制到剪贴板 由 Springer Nature SharedIt 内容共享计划提供
{"title":"Correction: Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)","authors":"Huei-Jen Chen, Yi-An Cheng, Yu-Tung Chen, Chia-Ching Li, Bo-Cheng Huang, Shih-Ting Hong, I.-Ju Chen, Kai-Wen Ho, Chiao-Yun Chen, Fang-Ming Chen, Jaw-Yuan Wang, Steve R. Rofer, Tian-Lu Cheng, Tung-Ho Wu","doi":"10.1186/s12645-024-00280-4","DOIUrl":"https://doi.org/10.1186/s12645-024-00280-4","url":null,"abstract":"<p><b>Correction: Cancer Nanotechnology (2023) 14:78 </b><b>https://doi.org/10.1186/s12645-023-00230-6</b></p><p>In this article, the author name Tung-Ho Wu was incorrectly written as Dung-Ho Wu. The affiliation of the author is given in this correction.</p><p>The original article has been corrected.</p><h3>Authors and Affiliations</h3><ol><li><p>Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung, 80708, Taiwan</p><p>Huei-Jen Chen, Yi-An Cheng, Bo-Cheng Huang & Tian-Lu Cheng</p></li><li><p>Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Huei-Jen Chen, Yu-Tung Chen, Chia-Ching Li, Shih-Ting Hong & Steve R. Rofer</p></li><li><p>Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Bo-Cheng Huang, I.-Ju Chen, Kai-Wen Ho, Chiao-Yun Chen, Jaw-Yuan Wang & Tian-Lu Cheng</p></li><li><p>Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan</p><p>Tian-Lu Cheng</p></li><li><p>Department of Medical Imaging, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan</p><p>Chiao-Yun Chen</p></li><li><p>School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Chiao-Yun Chen</p></li><li><p>Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan</p><p>Fang-Ming Chen</p></li><li><p>Department of Surgery, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan</p><p>Fang-Ming Chen</p></li><li><p>Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Fang-Ming Chen</p></li><li><p>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan</p><p>Steve R. Rofer</p></li><li><p>Department of Cardiovascular Surgeon, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan</p><p>Tung-Ho Wu</p></li><li><p>School of Medicine, I-Shou University, Kaohsiung, Taiwan</p><p>I.-Ju Chen</p></li></ol><span>Authors</span><ol><li><span>Huei-Jen Chen</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Yi-An Cheng</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Yu-Tung Chen</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Chia-Ching Li</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Bo-Cheng Huang</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Shih-Ting Hong</span>View author publications<p>You can also search for this author in <span>P","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"530 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141942364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-30DOI: 10.1186/s12645-024-00279-x
Kousain Kousar, Faiza Naseer, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad
<p><b>Retraction</b><b>: </b><b>Cancer Nanotechnology (2023) 14:71 </b><b>https://doi.org/10.1186/s12645-023-00220-8</b></p><p>The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding overlapping images in the presented data. Specifically:</p><p>Multiple images in Fig. 8a appear highly similar to those in Fig. 17 in Naseer et al. (2023), representing different groups.</p><p>Multiple images in Fig. 8b appear highly similar to those in Fig. 18 in Naseer et al. (2023), representing different groups.</p><ul> <li> <p>Fig. 8a D1 appears highly similar to Fig. 8b D3.</p> </li> <li> <p>Fig. 8a E1 and E2 appear to overlap with different magnification.</p> </li> <li> <p>Fig. 9a A5 insert (low magnification image) appears highly similar to that in B5.</p> </li> <li> <p>Fig. 9a A9 and b D7 appear to overlap with different contrast.</p> </li> <li> <p>Fig. 9a A10, A12 and B10 appear to overlap.</p> </li> <li> <p>Fig. 9a B1 and b C1, C3 appear to overlap with different magnification.</p> </li> <li> <p>Fig. 9a B3 and b C2, D2 appear to overlap with different magnification and contrast.</p> </li> <li> <p>Fig. 9a B4 and b D4 appear to overlap.</p> </li> <li> <p>Fig. 9a B10 and B11 appear to overlap.</p> </li> </ul><p>Additionally, the rat body weight data presented in Fig. 5a (~ 160 g at week 1) appear to be contrary to the description in the Methods (200–250 g).</p><p>The Editors-in-Chief therefore no longer have confidence in the presented data.</p><p>None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.</p><ul data-track-component="outbound reference" data-track-context="references section"><li><p>Naseer F, Kousar K, Abduh MS et al (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation. Cancer Nanotechnol 14:65. https://doi.org/10.1186/s12645-023-00218-2</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden="true" focusable="false" height="16" role="img" width="16"><use xlink:href="#icon-eds-i-download-medium" xmlns:xlink="http://www.w3.org/1999/xlink"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan</p><p>Kousain Kousar, Faiza Naseer & Tahir Ahmad</p></li><li><p>Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan</p><p>Faiza Naseer</p></li><li><p>Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><
撤稿：Cancer Nanotechnology (2023) 14:71 https://doi.org/10.1186/s12645-023-00220-8The 主编已撤回这篇文章。文章发表后，有人对文中数据中的重叠图像提出了质疑。具体来说：图 8a 中的多幅图像与 Naseer 等人（2023 年）的图 17 中的图像高度相似，代表不同的组别。图 8b 中的多幅图像与 Naseer 等人（2023 年）的图 18 中的图像高度相似，代表不同的组别。图 9a A5 插页（低放大率图像）与 B5 中的插页高度相似。图 9a A9 和 b D7 以不同的对比度出现重叠。此外，图 5a 中显示的大鼠体重数据（第 1 周时约为 160 克）似乎与《方法》中的描述（200-250 克）相反。Naseer F, Kousar K, Abduh MS et al (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation.Cancer Nanotechnol 14:65. https://doi.org/10.1186/s12645-023-00218-2Article CAS Google Scholar Download references作者及工作单位巴基斯坦伊斯兰堡国立科技大学阿塔-乌尔-拉赫曼应用生物科学学院工业生物技术Kousain Kousar, Faiza Naseer &；Tahir Ahmad巴基斯坦伊斯兰堡希法塔梅尔-伊-米拉特大学希法制药科学学院法伊扎-纳西尔沙特阿拉伯吉达 21589 阿卜杜勒-阿齐兹国王大学应用医学系医学实验室科学系不同疾病中的免疫反应研究小组麦萨-S.AbduhCenter of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi ArabiaMaisa S. AbduhDepartment of Biology, University of Hail, Hail, Saudi ArabiaSadia AnjumAuthorsKousain KousarView author publications您也可以在PubMed Google Scholar中搜索该作者Faiza NaseerView author publications您也可以在PubMed Google Scholar中搜索该作者Maisa S. Abduh查看作者发表的论文Abduh查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者Sadia Anjum查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者Tahir Ahmad查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者通信作者Kousain Kousar或Tahir Ahmad.Publisher's NoteSpringer Nature对出版地图和机构隶属关系中的管辖权主张保持中立。开放获取 本文采用知识共享署名 4.0 国际许可协议，该协议允许以任何媒介或格式使用、共享、改编、分发和复制本文，但必须注明原作者和出处，提供知识共享许可协议的链接，并说明是否进行了修改。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中，除非在材料的署名栏中另有说明。如果材料未包含在文章的知识共享许可协议中，且您打算使用的材料不符合法律规定或超出许可使用范围，您需要直接从版权所有者处获得许可。如需查看该许可的副本，请访问 http://creativecommons.org/licenses/by/4.0/。创意共享公共领域专用免责声明（http://creativecommons.org/publicdomain/zero/1.0/）适用于本文提供的数据，除非在数据的信用行中另有说明。 引用本文Kousar, K., Naseer, F., Abduh, M.S. et al. Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts.Cancer Nano 15, 40 (2024). https://doi.org/10.1186/s12645-024-00279-xDownload citationPublished: 30 July 2024DOI: https://doi.org/10.1186/s12645-024-00279-xShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative.
{"title":"Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts","authors":"Kousain Kousar, Faiza Naseer, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad","doi":"10.1186/s12645-024-00279-x","DOIUrl":"https://doi.org/10.1186/s12645-024-00279-x","url":null,"abstract":"<p><b>Retraction</b><b>: </b><b>Cancer Nanotechnology (2023) 14:71 </b><b>https://doi.org/10.1186/s12645-023-00220-8</b></p><p>The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding overlapping images in the presented data. Specifically:</p><p>Multiple images in Fig. 8a appear highly similar to those in Fig. 17 in Naseer et al. (2023), representing different groups.</p><p>Multiple images in Fig. 8b appear highly similar to those in Fig. 18 in Naseer et al. (2023), representing different groups.</p><ul>\u0000<li>\u0000<p>Fig. 8a D1 appears highly similar to Fig. 8b D3.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 8a E1 and E2 appear to overlap with different magnification.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a A5 insert (low magnification image) appears highly similar to that in B5.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a A9 and b D7 appear to overlap with different contrast.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a A10, A12 and B10 appear to overlap.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B1 and b C1, C3 appear to overlap with different magnification.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B3 and b C2, D2 appear to overlap with different magnification and contrast.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B4 and b D4 appear to overlap.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B10 and B11 appear to overlap.</p>\u0000</li>\u0000</ul><p>Additionally, the rat body weight data presented in Fig. 5a (~ 160 g at week 1) appear to be contrary to the description in the Methods (200–250 g).</p><p>The Editors-in-Chief therefore no longer have confidence in the presented data.</p><p>None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.</p><ul data-track-component=\"outbound reference\" data-track-context=\"references section\"><li><p>Naseer F, Kousar K, Abduh MS et al (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation. Cancer Nanotechnol 14:65. https://doi.org/10.1186/s12645-023-00218-2</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan</p><p>Kousain Kousar, Faiza Naseer & Tahir Ahmad</p></li><li><p>Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan</p><p>Faiza Naseer</p></li><li><p>Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"154 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141867552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-27DOI: 10.1186/s12645-024-00278-y
Faiza Naseer, Kousain Kousar, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad
<br/><p><b>Retraction Note: Cancer Nanotechnology (2023) 14:65</b> <b>https://doi.org/10.1186/s12645-023-00218-2</b></p><br/><p>The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding some of the images presented in the figures, specifically:</p><ul> <li> <p>Fig. 6 appears highly similar to Fig. 10 of Naseer et al. (2023)</p> </li> <li> <p>Fig. 6 Pure VC 12 h 90 ug/ml and VC-loaded TCs-HA 24 h 50 ug/ml images appear highly similar</p> </li> <li> <p>Fig. 17 A5 and Fig. 18 D5 images appear to overlap (flipped and with different magnification)</p> </li> <li> <p>Fig. 18 C6 and D6 appear to overlap (with different magnification)</p> </li> <li> <p>Several panels in Figs. 17 and 18 appear highly similar to those in Fig. 8 of Kousar et al. (2023)</p> </li> </ul><p>The authors have been unable to provide the underlying raw data upon request. The Editors-in-Chief therefore no longer have confidence in the presented data.</p><p>None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.</p><ul data-track-component="outbound reference" data-track-context="references section"><li><p>Naseer F, Ahmad T, Kousar K, Kakar S, Gul R, Anjum S, Shareef U (2023) Formulation for the targeted delivery of a vaccine strain of oncolytic measles virus (OMV) in hyaluronic acid coated thiolated chitosan as a green nanoformulation for the treatment of prostate cancer: a viro-immunotherapeutic approach. Int J Nanomed 18:185–205. https://doi.org/10.2147/IJN.S386560</p><p>Article CAS Google Scholar </p></li><li><p>Kousar K, Naseer F, Abduh MS et al (2023) Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts. Cancer Nano 14:71. https://doi.org/10.1186/s12645-023-00220-8</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden="true" focusable="false" height="16" role="img" width="16"><use xlink:href="#icon-eds-i-download-medium" xmlns:xlink="http://www.w3.org/1999/xlink"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan</p><p>Faiza Naseer, Kousain Kousar & Tahir Ahmad</p></li><li><p>Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan</p><p>Faiza Naseer</p></li><li><p>Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Department of Biology, University of Hail, Hail, Saudi Arabia</p><p>Sadia Anjum</p></li></ol><span>Authors</span><ol><li><span>Faiza Naseer</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Sch
撤稿说明：Cancer Nanotechnology (2023) 14:65 https://doi.org/10.1186/s12645-023-00218-2The 主编已撤回这篇文章。图 6 纯 VC 12 h 90 ug/ml 和 VC-loaded TCs-HA 24 h 50 ug/ml 的图像高度相似。图 17 A5 和图 18 D5 的图像出现重叠（翻转且放大倍数不同）。图 17 和 18 中的几个面板与 Kousar 等人（2023 年）的图 8 中的面板高度相似。因此，主编对所提供的数据不再有信心。作者均未回复编辑或出版商有关撤稿通知的任何信件。Naseer F, Ahmad T, Kousar K, Kakar S, Gul R, Anjum S, Shareef U (2023) 在透明质酸包覆的硫醇化壳聚糖中靶向递送溶瘤麻疹病毒（OMV）疫苗株的制剂，作为治疗前列腺癌的绿色纳米制剂：一种病毒免疫治疗方法。https://doi.org/10.2147/IJN.S386560Article CAS Google Scholar Kousar K, Naseer F, Abduh MS et al (2023) Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts.Cancer Nano 14:71. https://doi.org/10.1186/s12645-023-00220-8Article CAS Google Scholar Download references作者和工作单位巴基斯坦伊斯兰堡国立科技大学阿塔-乌尔-拉赫曼应用生物科学学院工业生物技术Faiza Naseer, Kousain Kousar &；Tahir Ahmad巴基斯坦伊斯兰堡希法 Tameer e Millat 大学希法制药科学学院Faiza Naseer沙特阿拉伯吉达 21589 阿卜杜勒-阿齐兹国王大学应用医学科学院医学实验室科学系不同疾病中的免疫反应研究小组Maisa S. AbduhDepartment of Biology, Kousain Kousar &.AbduhDepartment of Biology, University of Hail, Hail, Saudi ArabiaSadia AnjumAuthorsFaiza NaseerView author publications您也可以在PubMed Google Scholar中搜索该作者Kousain KousarView author publications您也可以在PubMed Google Scholar中搜索该作者Maisa S. Abduh查看作者发表的文章Abduh查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者Sadia Anjum查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者Tahir Ahmad查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者通信作者通信作者：Faiza Naseer或Tahir Ahmad.Publisher's NoteSpringer Nature对出版地图和机构隶属关系中的管辖权主张保持中立。开放获取 本文采用知识共享署名 4.0 国际许可协议，该协议允许以任何媒介或格式使用、共享、改编、分发和复制本文，但必须注明原作者和出处，提供知识共享许可协议的链接，并说明是否进行了修改。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中，除非在材料的署名栏中另有说明。如果材料未包含在文章的知识共享许可协议中，且您打算使用的材料不符合法律规定或超出许可使用范围，则您需要直接从版权所有者处获得许可。要查看该许可的副本，请访问 http://creativecommons.org/licenses/by/4.0/。除非在数据的信用行中另有说明，否则创作共用公共领域专用免责声明 (http://creativecommons.org/publicdomain/zero/1.0/) 适用于本文提供的数据。引用本文Naseer, F., Kousar, K., Abduh, M.S. et al. Retraction Note: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation.Cancer Nano 15, 39 (2024). https://doi.org/10.1186/s12645-024-00278-yDownload citationPublished: 27 July 2024DOI: https://doi.org/10.1186/s12645-024-00278-yShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
{"title":"Retraction Note: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation","authors":"Faiza Naseer, Kousain Kousar, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad","doi":"10.1186/s12645-024-00278-y","DOIUrl":"https://doi.org/10.1186/s12645-024-00278-y","url":null,"abstract":"<br/><p><b>Retraction Note: Cancer Nanotechnology (2023) 14:65</b> <b>https://doi.org/10.1186/s12645-023-00218-2</b></p><br/><p>The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding some of the images presented in the figures, specifically:</p><ul>\u0000<li>\u0000<p>Fig. 6 appears highly similar to Fig. 10 of Naseer et al. (2023)</p>\u0000</li>\u0000<li>\u0000<p>Fig. 6 Pure VC 12 h 90 ug/ml and VC-loaded TCs-HA 24 h 50 ug/ml images appear highly similar</p>\u0000</li>\u0000<li>\u0000<p>Fig. 17 A5 and Fig. 18 D5 images appear to overlap (flipped and with different magnification)</p>\u0000</li>\u0000<li>\u0000<p>Fig. 18 C6 and D6 appear to overlap (with different magnification)</p>\u0000</li>\u0000<li>\u0000<p>Several panels in Figs. 17 and 18 appear highly similar to those in Fig. 8 of Kousar et al. (2023)</p>\u0000</li>\u0000</ul><p>The authors have been unable to provide the underlying raw data upon request. The Editors-in-Chief therefore no longer have confidence in the presented data.</p><p>None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.</p><ul data-track-component=\"outbound reference\" data-track-context=\"references section\"><li><p>Naseer F, Ahmad T, Kousar K, Kakar S, Gul R, Anjum S, Shareef U (2023) Formulation for the targeted delivery of a vaccine strain of oncolytic measles virus (OMV) in hyaluronic acid coated thiolated chitosan as a green nanoformulation for the treatment of prostate cancer: a viro-immunotherapeutic approach. Int J Nanomed 18:185–205. https://doi.org/10.2147/IJN.S386560</p><p>Article CAS Google Scholar </p></li><li><p>Kousar K, Naseer F, Abduh MS et al (2023) Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts. Cancer Nano 14:71. https://doi.org/10.1186/s12645-023-00220-8</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan</p><p>Faiza Naseer, Kousain Kousar & Tahir Ahmad</p></li><li><p>Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan</p><p>Faiza Naseer</p></li><li><p>Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Department of Biology, University of Hail, Hail, Saudi Arabia</p><p>Sadia Anjum</p></li></ol><span>Authors</span><ol><li><span>Faiza Naseer</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Sch","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"5 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141772924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-22DOI: 10.1186/s12645-024-00276-0
Malgorzata Sikorska, Grzegorz Domanski, Magdalena Bamburowicz-Klimkowska, Artur Kasprzak, Anna M. Nowicka, Monika Ruzycka-Ayoush, Ireneusz P. Grudzinski
Magnetic fluid hyperthermia (MFH) represents a promising therapeutic strategy in cancer utilizing the heating capabilities of magnetic nanoparticles when exposed to an alternating magnetic field (AMF). Because the efficacy and safety of MFH treatments depends on numerous intrinsic and extrinsic factors, therefore, the proper MFH setups should focus on thermal energy dosed into the cancer cells. In this study, we performed MFH experiments using human lung cancer A549 cells (in vitro) and NUDE Balb/c mice bearing human lung (A549) cancer (in vivo). In these two experimental models, the heat was induced by magnesium-doped iron(III) oxide nanoparticles coated with mPEG-silane (Mg0.1-γ-Fe2O3(mPEG-silane)0.5) when exposed to an AMF. We observed that the lung cancer cells treated with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 (0.25 mg·mL−1) and magnetized for 30 min at 14.4 kA·m−1 yielded a satisfactory outcome in reducing the cell viability up to ca. 21% (in vitro). The activation energy calculated for this field strength was estimated for 349 kJ·mol−1. Both volumetric measurements and tumor mass assessments confirmed by magnetic resonance imaging (MRI) showed a superior thermal effect in mice bearing human lung cancer injected intratumorally with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 nanoparticles (3 mg·mL−1) and subjected to an AMF (18.3 kA·m−1) for 30 min four times at weekly intervals. Research demonstrated that mice undergoing MFH exhibited a marked suppression of tumor growth (V = 169 ± 94 mm3; p < 0.05) in comparison to the control group of untreated mice. The CEM43 (cumulative number of equivalent minutes at 43 °C) value for these treatments were estimated for ca. 9.6 min with the specific absorption rate (SAR) level ranging from 100 to 150 W·g−1. The as-obtained results, both cytotoxic and those related to energy calculations and SAR, may contribute to the advancement of thermal therapies, concurrently indicating that the proposed magnetic fluid hyperthermia holds a great potential for further testing in the context of medical applications.
{"title":"Studies on the thermal sensitivity of lung cancer cells exposed to an alternating magnetic field and magnesium-doped maghemite nanoparticles","authors":"Malgorzata Sikorska, Grzegorz Domanski, Magdalena Bamburowicz-Klimkowska, Artur Kasprzak, Anna M. Nowicka, Monika Ruzycka-Ayoush, Ireneusz P. Grudzinski","doi":"10.1186/s12645-024-00276-0","DOIUrl":"https://doi.org/10.1186/s12645-024-00276-0","url":null,"abstract":"Magnetic fluid hyperthermia (MFH) represents a promising therapeutic strategy in cancer utilizing the heating capabilities of magnetic nanoparticles when exposed to an alternating magnetic field (AMF). Because the efficacy and safety of MFH treatments depends on numerous intrinsic and extrinsic factors, therefore, the proper MFH setups should focus on thermal energy dosed into the cancer cells. In this study, we performed MFH experiments using human lung cancer A549 cells (in vitro) and NUDE Balb/c mice bearing human lung (A549) cancer (in vivo). In these two experimental models, the heat was induced by magnesium-doped iron(III) oxide nanoparticles coated with mPEG-silane (Mg0.1-γ-Fe2O3(mPEG-silane)0.5) when exposed to an AMF. We observed that the lung cancer cells treated with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 (0.25 mg·mL−1) and magnetized for 30 min at 14.4 kA·m−1 yielded a satisfactory outcome in reducing the cell viability up to ca. 21% (in vitro). The activation energy calculated for this field strength was estimated for 349 kJ·mol−1. Both volumetric measurements and tumor mass assessments confirmed by magnetic resonance imaging (MRI) showed a superior thermal effect in mice bearing human lung cancer injected intratumorally with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 nanoparticles (3 mg·mL−1) and subjected to an AMF (18.3 kA·m−1) for 30 min four times at weekly intervals. Research demonstrated that mice undergoing MFH exhibited a marked suppression of tumor growth (V = 169 ± 94 mm3; p < 0.05) in comparison to the control group of untreated mice. The CEM43 (cumulative number of equivalent minutes at 43 °C) value for these treatments were estimated for ca. 9.6 min with the specific absorption rate (SAR) level ranging from 100 to 150 W·g−1. The as-obtained results, both cytotoxic and those related to energy calculations and SAR, may contribute to the advancement of thermal therapies, concurrently indicating that the proposed magnetic fluid hyperthermia holds a great potential for further testing in the context of medical applications. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"1 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141742301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：